Tonix Pharmaceuticals, Inc.

219 articles with Tonix Pharmaceuticals, Inc.

• Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit

  3/23/2020

  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting a virtual presentation in conjunction with the Spring Investor Summit on Wednesday, March 25, 2020, at 1:50 p.m. ET.

• Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering

  3/3/2020

  TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offeringother estimated offering expenses. The Company sold 14,550,000 shares of common stock at $1.10 per share. Following the offering, the Company had an aggregate of 49,227,634 shares o

• Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market

  2/28/2020

  TONIX PHARMACEUTICALS, INC. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 14,550,000 shares of common stock, par value $0.001 per share at an offering price of $1.10 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules.

• Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)

  2/26/2020

  NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800* (live modified horsepox virus vaccine for percutaneous administration) to protect against the new coronavirus disease, COVID-19, based on Tonix’s proprietary horsepox vaccine platform.  Tonix is developing TNX-801 (live

• Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering

  2/11/2020

  Tonix Pharmaceuticals Holding Corp. announced the closing of its previously announced underwritten public offering with total gross proceeds of approximately $7,500,000 before deducting underwriting discounts, commissions and other offering expenses payable by the Company.

• Tonix Pharmaceuticals Prices $7.5 million Public Offering

  2/7/2020

  NEW YORK, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering with expected total gross proceeds of $7.5 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company. The securities offered by the Company consist of (i) 3,837,000 Class A Units, each Class A Unit consisting of one

• Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD

  2/5/2020

  RECOVERY Study has Stopped Enrollment Due to Inadequate Separation from Placebo at Week-12 Based on Interim Analysis Results of the First 50% of Enrolled Participants

• Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference

  1/29/2020

  Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, presented preclinical results of TNX-801 to potentially prevent smallpox and monkeypox in a poster at the 2020 ASM Biothreats Conference held January 28-30, 2020 in Arlington, Va.

• Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL

  1/24/2020

  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a clinical-stage biopharmaceutical company, today announced that it has completed the required fed-fasting and dose proportionality tests of TNX-102 SL in healthy volunteers to support the New Drug Application (NDA) of TNX-102 SL for the treatment of posttraumatic stress disorder (PTSD) and fibromyalgia.

• Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference

  1/23/2020

  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will be presenting preclinical results of TNX-801 in a poster at the 2020 ASM Biothreats Conference

• Tonix Pharmaceuticals to Present at Biotech Showcase 2020

  1/7/2020

  Tonix Pharmaceuticals Holding Corp. announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and conduct investor meetings at Biotech Showcase 2020 being held January 13-15, 2020 at the Hilton San Francisco Union Square.

• Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic Study

  12/16/2019

  TNX-601 CR Active Ingredient, Tianeptine, is Approved and Marketed as an Immediate Release Three-Times-a-Day Antidepressant in Europe, Asia, Russia and Latin America

• Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL

  12/11/2019

  Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that the European Patent Office issued European Patent No. 2968992 to the Company on December 11, 2019.

• Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

  12/10/2019

  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first patient was enrolled in the Phase 3 RELIEF study (TNX-CY-F304).

• Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event

  12/4/2019

  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at the 12th Annual LD Micro Main Event being held December 10-12, 2019, in Bel-Air, Calif.

• Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

  12/3/2019

  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on the NASDAQ Global Market.

• Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference

  11/25/2019

  Tonix Pharmaceuticals Holding Corp. announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting investor meetings at Benchmark’s 8th Annual Discovery 1x1 Conference being held December 4, 2019, at the New York Athletic Club in New York City.

• Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of FibromyalgiaFirst Patient Expected to be Dosed Before Year-End 2019

  11/21/2019

  Tonix Pharmaceuticals Holding Corp. announced that, having successfully closed an underwritten public equity offering for $9.0 million, it has initiated the Phase 3 RELIEF study.

• Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder

  11/20/2019

  FDA Official Meeting Minutes Support Tonix’s Plan to file an Investigational New Drug (IND) Application in the First Quarter of 2020 for a Phase 2 Proof-of-Concept Study

• Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering

  11/20/2019

  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offering with total gross proceeds of approximately $9,000,000 before deducting underwriting discounts, commissions and other offering expenses payable by the Company.